Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Go back to Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)| (NASDAQ: IONS) | Delayed: 76.83 +0.84 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.99 | 52 Week High | $62.68 | |||
| Open | $76.40 | 52 Week Low | $19.59 | |||
| Day High | $79.00 | P/E | N/A | |||
| Day Low | $76.04 | EPS | $0.00 | |||
| Volume | 1,315,770 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 23.99 -0.73 (2.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.80 | 52 Week Low | $28.25 | |||
| Day High | $25.11 | P/E | 14.54 | |||
| Day Low | $23.98 | EPS | $1.65 | |||
| Volume | 41,695,771 | |||||
